Integrated Filing — IndAS

General information about company
Scrip Code	532612
NSE Symbol	INDOCO
MSEI Symbol	NOTLISTED
ISIN	INE873D01024
Name of company	INDOCO REMEDIES LIMITED
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-Apr-2024
Date of end of financial year	31-Mar-2025
Date of board meeting when results were approved	22-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	14-May-2025
Description of presentation currency	INR (in Actuals)
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Pharmaceuticals
Start date and time of board meeting	22-May-2025   12:56:00
End date and time of board meeting	22-May-2025   14:25:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	2025-03-25
Indicate Company website link for updated RPT policy of the Company	https://www.indoco.com/policies/Policy_on_Materiality_of_Related_Party_Transactions_March2025.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No
During the reporting period, the Company does not have debt securities and there is no default on the loan taken by the Company.

Financial Results Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	3472500000	15181900000
	Other income	65000000	184800000
	Total income	3537500000	15366700000
2	Expenses
(a)	Cost of materials consumed	722200000	3347900000
(b)	Purchases of stock-in-trade	306200000	1409300000
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-129800000	-320400000
(d)	Employee benefit expense	999400000	3687400000
(e)	Finance costs	159800000	566300000
(f)	Depreciation, depletion and amortisation expense	248800000	982500000
(f)	Other Expenses
1	Research & Development Expenses	173900000	760100000
2	Other Expenses	1366000000	5017200000
	Total other expenses	1539900000	5777300000
	Total expenses	3846500000	15450300000
3	Total profit before exceptional items and tax	-309000000	-83600000
4	Exceptional items	0	9900000
5	Total profit before tax	-309000000	-73700000
6	Tax expense
7	Current tax	-29300000	0
8	Deferred tax	-17300000	13600000
9	Total tax expenses	-46600000	13600000
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	-262400000	-87300000
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	-262400000	-87300000
17	Other comprehensive income net of taxes	-38200000	-44900000
18	Total Comprehensive Income for the period	-300600000	-132200000
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent
	Total profit or loss, attributable to non-controlling interests
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent
	Total comprehensive income for the period attributable to owners of parent non-controlling interests
21	Details of equity share capital
	Paid-up equity share capital	184500000	184500000
	Face value of equity share capital	2	2
27	Details of debt securities
22	Reserves excluding revaluation reserve		10849100000
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	-2.85	-0.95
	Diluted earnings (loss) per share from continuing operations	-2.84	-0.95
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	-2.85	-0.95
	Diluted earnings (loss) per share from continuing and discontinued operations	-2.84	-0.95
24	Debt equity ratio	0	0
25	Debt service coverage ratio
26	Interest service coverage ratio
27	Disclosure of notes on financial results		1. The Audited Standalone Results for the Quarter and year ended 31st March, 2025 have been reviewed by the Audit committee and approved by the Board of Directors of the Company at its meeting held on 22nd May, 2025. The Statutory Auditors have expressed an Unmodified Audit opinion on these audited Standalone Financial Results. n n2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. n n3. The Board of Directors have proposed, subject to the approval of shareholders in the ensuing Annual General Meeting a Dividend of 10% i.e. Rs. 0.20 per equity share on face value of Rs. 2/-each to its equity shareholder's for the year 2024-2025. n n4. In Nomination & Remuneration Committee meeting held on 21st January,2025, the Company has allotted 65,700 number of equity shares to Indoco Employees WelfareTrust under Indoco Remedies Limited Employee Stock Option Plan 2022. n n5. The company has only one primary reportable segment of activity, namely, Pharmaceuticals. n n6. Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: n (Rs in lakhs) n--------------------------------------------------------------------------------------------------------------------------------- nNet Sales Qtr ended Qtr ended Qtr ended Year ended Year ended nand Income 31-03-2025 31-12-2024 31-03-2024 31-03-2025 31-03-2024 nfrom Operations (Audited) (Unaudited) (Audited) (Audited) (Audited) n---------------------------------------------------------------------------------------------------------------------------------- nIndia 21,639 23,935 20,816 91,598 92,431 nOutside India 12,468 12,556 22,698 57,880 83,764 n----------------------------------------------------------------------------------------------------------------------------------- nTotal 34,107 36,491 43,514 1,49,478 1,76,195 n--------------------------------------------------------------------------------------------------------------------------------- n7. Figures for the quarter ended 31-03-2025 and 31-03-2024 represents the difference between audited figures in respect of the full financial year and published figures for the period ended 31-12-2024 (limited reviewed) and 31-12-2023 (limited reviewed) n n8. (*)Exceptional items include consideration received Rs. 99.4 lacs for grant to use exclusive,perpetual and irrevocable license rights in respect of trademarks of the company.

Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-Apr-2024
Date of end of reporting period		31-Mar-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	Assets
1	Non-current assets
	Property, plant and equipment	6706200000
	Capital work-in-progress	1813700000
	Investment property
	Goodwill	0
	Other intangible assets	837600000
	Intangible assets under development	444200000
	Biological assets other than bearer plants
	Investments accounted for using equity method
	Non-current financial assets
	Non-current investments	519600000
	Trade receivables, non-current
	Loans, non-current	1202500000
	Other non-current financial assets	59500000
	Total non-current financial assets	1781600000
	Deferred tax assets (net)	0
	Other non-current assets	873600000
	Total non-current assets	12456900000
2	Current assets
	Inventories	3628700000
	Current financial asset
	Current investments	0
	Trade receivables, current	3740500000
	Cash and cash equivalents	70600000
	Bank balance other than cash and cash equivalents	49700000
	Loans, current	198800000
	Other current financial assets	277900000
	Total current financial assets	4337500000
	Current tax assets (net)	183400000
	Other current assets	1405100000
	Total current assets	9554700000
3	Non-current assets classified as held for sale
4	Regulatory deferral account debit balances and related deferred tax Assets
	Total assets	22011600000
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	184500000
	Other equity	10849100000
	Total equity attributable to owners of parent	11033600000
	Non controlling interest
	Total equity	11033600000
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	3462500000
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
	Total Trade payable
	Other non-current financial liabilities	43900000
	Total non-current financial liabilities	3506400000
	Provisions, non-current	348900000
	Deferred tax liabilities (net)	98500000
	Deferred government grants, Non-current
	Other non-current liabilities	74100000
	Total non-current liabilities	4027900000
	Current liabilities
	Current financial liabilities
	Borrowings, current	4072700000
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	277400000
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	1196400000
	Total Trade payable	1473800000
	Other current financial liabilities	730500000
	Total current financial liabilities	6277000000
	Other current liabilities	222400000
	Provisions, current	450700000
	Current tax liabilities (Net)
	Deferred government grants, Current
	Total current liabilities	6950100000
3	Liabilities directly associated with assets in disposal group classified as held for sale
4	Regulatory deferral account credit balances and related deferred tax liability
	Total liabilities	10978000000
	Total equity and liabilites	22011600000
	Disclosure of notes on assets and liabilities

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-Jan-2025	01-Apr-2024
Date of end of reporting period		31-Mar-2025	31-Mar-2025
Whether accounts are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
	Total Segment Revenue
	Less: Inter segment revenue
	Revenue from operations
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
	Total Profit before tax
	i. Finance cost
	ii. Other Unallocable Expenditure net off Unallocable income
	Profit before tax
3	(Segment Asset - Segment Liabilities)
	Segment Asset
	Total Segment Asset
	Un-allocable Assets	null	null
	Net Segment Asset	null	null
4	Segment Liabilities
	Segment Liabilities
	Total Segment Liabilities
	Un-allocable Liabilities	null	null
	Net Segment Liabilities	null	null
	Disclosure of notes on segments

Other Comprehensive Income
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
1	Item that will not be classified to profit & loss	-51000000	-60000000
	Total Amount of items that will not be reclassified to profit and loss	-51000000	-60000000
2	Income tax relating to items that will not be reclassified to profit or loss	-12800000	-15100000
3	Amount of items that will be reclassified to profit and loss
	Total Amount of items that will be reclassified to profit and loss
4	Income tax relating to items that will be reclassified to profit or loss	0	0
5	Total Other comprehensive income	-38200000	-44900000

Cash flow statement, indirect
Particulars				Year ended (dd-mm-yyyy)
A	Date of start of reporting period			2024-04-01
B	Date of end of reporting period			2025-03-31
C	Whether results are audited or unaudited			Audited
D	Nature of report standalone or consolidated			Standalone
Part I	Blue color marked fields are non-mandatory.
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax			-73700000
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs			566400000
	Adjustments for decrease (increase) in inventories			-524500000
	Adjustments for decrease (increase) in trade receivables, current			309900000
	Adjustments for decrease (increase) in trade receivables, non-current			0
	Adjustments for decrease (increase) in other current assets			-125900000
	Adjustments for decrease (increase) in other non-current assets			-800000
	Adjustments for other financial assets, non-current			100000
	Adjustments for other financial assets, current			-194200000
	Adjustments for other bank balances			0
	Adjustments for increase (decrease) in trade payables, current			291800000
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			84500000
	Adjustments for increase (decrease) in other non-current liabilities			0
	Adjustments for depreciation and amortisation expense			982500000
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			0
	Adjustments for provisions, current			-32100000
	Adjustments for provisions, non-current			-45800000
	Adjustments for other financial liabilities, current			-123000000
	Adjustments for other financial liabilities, non-current			35200000
	Adjustments for unrealised foreign exchange losses gains			13900000
	Adjustments for dividend income			0
	Adjustments for interest income			115900000
	Adjustments for share-based payments			18700000
	Adjustments for fair value losses (gains)			0
	Adjustments for undistributed profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			0
	Other adjustments to reconcile profit (loss)			8200000
	Other adjustments for non-cash items			-1600000
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			1147400000
	Net cash flows from (used in) operations			1073700000
	Dividends received			0
	Interest paid			0
	Interest received			0
	Income taxes paid (refund)			166000000
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) operating activities			907700000
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			0
	Other cash receipts from sales of equity or debt instruments of other entities			79000000
	Other cash payments to acquire equity or debt instruments of other entities			0
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships			0
	Proceeds from sales of property, plant and equipment			35500000
	Purchase of property, plant and equipment			2584300000
	Proceeds from sales of investment property			0
	Purchase of investment property			0
	Proceeds from sales of intangible assets			0
	Purchase of intangible assets			0
	Proceeds from sales of intangible assets under development			0
	Purchase of intangible assets under development			0
	Proceeds from sales of goodwill			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			0
	Proceeds from sales of other long-term assets			0
	Purchase of other long-term assets			0
	Cash advances and loans made to other parties			289000000
	Cash receipts from repayment of advances and loans made to other parties			0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts			0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts			0
	Dividends received			0
	Interest received			115900000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			45000000
	Net cash flows from (used in) investing activities	-2597900000
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries			0
	Payments from changes in ownership interests in subsidiaries			0
	Proceeds from issuing shares			15900000
	Proceeds from issuing other equity instruments			0
	Payments to acquire or redeem entity's shares			0
	Payments of other equity instruments			0
	Proceeds from exercise of stock options			0
	Proceeds from issuing debentures notes bonds etc			0
	Proceeds from borrowings			2009900000
	Repayments of borrowings			-401500000
	Payments of lease liabilities			52300000
	Dividends paid			139000000
	Interest paid			549800000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) financing activities			1686200000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes			-4000000
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents			0
	Net increase (decrease) in cash and cash equivalents			-4000000
	Cash and cash equivalents cash flow statement at beginning of period			74700000
	Cash and cash equivalents cash flow statement at end of period			70700000